ImClone Development Update At ASCO Boosts Strong Performance In May
Executive Summary
ImClone System's development update for its epidermal growth factor receptor product at the American Society of Clinical Oncology annual meeting helped boost the firm's stock performance in May.
You may also be interested in...
Iressa Patients’ Lack Of Rash Suggests Dose Is Too Low For Benefit – OSI
Absence of rash in patients using AstraZeneca's Iressa suggests that the dose for the EGFR agent was not high enough to achieve clinical benefit, OSI Pharmaceuticals CEO Colin Goddard, PhD, said
Iressa Patients’ Lack Of Rash Suggests Dose Is Too Low For Benefit – OSI
Absence of rash in patients using AstraZeneca's Iressa suggests that the dose for the EGFR agent was not high enough to achieve clinical benefit, OSI Pharmaceuticals CEO Colin Goddard, PhD, said
Bristol/ImClone Erbitux BLA Resubmission Expected During First Quarter
ImClone expects to resubmit the BLA for Erbitux (cetuximab) during the first quarter after addressing the issues raised in FDA's "refuse-to-file" letter for the colorectal cancer treatment